PDF(Sci-hub)
Abstract：
OBJECTIVE: Health technology assessment (HTA) can increase the appropriateness and transparency of pricing and reimbursement decisions. Jordan is still in the early phase of its HTA implementation, although the country has very limited public resources for the coverage of healthcare technologies. The study objective was to explore and validate priorities in the HTA road map for Jordan and propose to facilitate the preferred HTA status.
METHODS: Health policy experts from the public and private sectors were asked to participate in a survey to explore the current and future status of HTA implementation in Jordan. Semistructured interviews with senior policy makers supported by literature review were conducted to validate survey results and make recommendations for specific actions.
RESULTS: Survey and interview results indicated a need for increased HTA training, including both short courses and academic programs and gradually increasing public funding for technology assessment and appraisal. Multiple HTA bodies with central coordination can be the most feasible format of HTA institutionalization. The weight of cost-effectiveness criterion based on local data with published reports and explicit decision thresholds should be increased in policy decisions of pharmaceutical and nonpharmaceutical technologies.
CONCLUSIONS: Currently, HTA has limited impact on health policy decisions in Jordan, and when it is used to support pharmaceutical reimbursement decisions, it is mainly based on results from other countries without considering transferability of international evidence. Policy makers should facilitate HTA institutionalization and use in policy decisions by increasing the weight of local evidence in HTA recommendations.
METHODS: Health policy experts from the public and private sectors were asked to participate in a survey to explore the current and future status of HTA implementation in Jordan. Semistructured interviews with senior policy makers supported by literature review were conducted to validate survey results and make recommendations for specific actions.
RESULTS: Survey and interview results indicated a need for increased HTA training, including both short courses and academic programs and gradually increasing public funding for technology assessment and appraisal. Multiple HTA bodies with central coordination can be the most feasible format of HTA institutionalization. The weight of cost-effectiveness criterion based on local data with published reports and explicit decision thresholds should be increased in policy decisions of pharmaceutical and nonpharmaceutical technologies.
CONCLUSIONS: Currently, HTA has limited impact on health policy decisions in Jordan, and when it is used to support pharmaceutical reimbursement decisions, it is mainly based on results from other countries without considering transferability of international evidence. Policy makers should facilitate HTA institutionalization and use in policy decisions by increasing the weight of local evidence in HTA recommendations.
摘要：
目的：卫生技术评估（HTA）可以提高定价和报销决策的适当性和透明度。约旦仍处于HTA实施的早期阶段，尽管该国用于医疗技术覆盖的公共资源非常有限。该研究的目的是探索和验证约旦HTA路线图中的优先事项，并建议促进首选HTA状态。
方法：来自公共和私营部门的卫生政策专家被要求参加一项调查，以探讨约旦实施HTA的当前和未来状况。在文献综述的支持下，对高级决策者进行了半结构化访谈，以验证调查结果并为具体行动提出建议。
结果：调查和访谈结果表明需要增加HTA培训，包括短期课程和学术课程，并逐步增加用于技术评估和评估的公共资金。具有中央协调的多个HTA机构可能是HTA制度化的最可行形式。在制药和非制药技术的政策决策中，应增加基于本地数据以及已发布报告和明确决策阈值的成本效益标准的权重。
结论：目前，HTA对约旦卫生政策决策的影响有限，当它被用来支持药品报销决定时，它主要基于其他国家的结果，没有考虑国际证据的可转移性。政策制定者应通过增加地方证据在HTA建议中的权重，促进HTA制度化和在政策决策中的使用。
方法：来自公共和私营部门的卫生政策专家被要求参加一项调查，以探讨约旦实施HTA的当前和未来状况。在文献综述的支持下，对高级决策者进行了半结构化访谈，以验证调查结果并为具体行动提出建议。
结果：调查和访谈结果表明需要增加HTA培训，包括短期课程和学术课程，并逐步增加用于技术评估和评估的公共资金。具有中央协调的多个HTA机构可能是HTA制度化的最可行形式。在制药和非制药技术的政策决策中，应增加基于本地数据以及已发布报告和明确决策阈值的成本效益标准的权重。
结论：目前，HTA对约旦卫生政策决策的影响有限，当它被用来支持药品报销决定时，它主要基于其他国家的结果，没有考虑国际证据的可转移性。政策制定者应通过增加地方证据在HTA建议中的权重，促进HTA制度化和在政策决策中的使用。
